We and others have demonstrated that modulation of adipocyte lipolysis via genetic ablation or pharmacological inhibition of ATGL improves systemic glucose homeostasis and insulin sensitivity, and protects against hepatic steatosis in the setting of diet- or genetically induced obesity6,7,9. This evidence concerns the gene INS and fatty liver disease.